Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference
April 03 2023 - 7:00AM
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune disease, today
announced that company management will participate in the 22nd
Annual Needham Virtual Healthcare Conference being held April
17-20, 2023.
Presentation Details
Conference: Needham 22nd Annual Healthcare
ConferenceFormat: Fireside chat with covering analyst Gil Blum,
Ph.D.Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief
Executive Officer and Andrew Neill, M.B.A., Shattuck’s Chief
Financial Officer Date: April 19, 2023Time: 2:15-2:55 p.m. ET
A live webcast of the fireside chat will be
available on the Investors section of the Company’s website. A
replay of the webcast will be archived for up to 90 days following
the presentation date.
About Shattuck Labs, Inc.Shattuck
Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company
pioneering the development of bi-functional fusion proteins as a
new class of biologic medicine for the treatment of patients with
cancer and autoimmune disease. Compounds derived from Shattuck’s
proprietary Agonist Redirected Checkpoint, ARC®, platform
simultaneously inhibit checkpoint molecules and activate
costimulatory molecules with a single therapeutic. The company’s
lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block
the CD47 immune checkpoint and simultaneously agonize the CD40
pathway, is being evaluated in multiple Phase 1 trials.
Additionally, the company is advancing a proprietary Gamma Delta T
Cell Engager, GADLEN™, platform, which is designed to bridge gamma
delta T cells to tumor antigens for the treatment of patients with
cancer. Shattuck has offices in both Austin, Texas and Durham,
North Carolina. For more information, please visit:
www.ShattuckLabs.com.
The Company intends to use the investor relations
portion of its website as a means of disclosing material non-public
information and for complying with disclosure obligations under
Regulation FD.
Investor & Media Contact:
Conor RichardsonVice President of Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024